Can Employers Take A Bigger Role In Controlling Drug Costs?
(2/17, Robert Galvin and Troyen Brennan, Health Affairs Blog) comments “...Outcome measures have proven very challenging to develop and acceptable metrics are likely to apply to only selected drugs. Process measures, e.g., decreasing cholesterol levels, vary considerably in their contribution to how patients fare. A variation of this approach, more likely to have greater impact in the short run, is indication-based pricing in which drugs are priced differentially based on evidence of their efficacy in the different conditions.” Full
What Is Real-World Evidence, and Why Do We Need It?
(2/16, Julie C. Locklear, PharmD, MBA, STAT) comments “...As the discussion about getting drugs to the marketplace continues, getting the information and the evidence right is critical. If we can do this, and do this successfully, we might one day be able to increase access to the right drugs for the right patients at the right time. Then we'll have better value for the dollars spent and most importantly, we'll be working to try and improve the health and lives of millions of patients.” Full
Going National a Possibility for Medicare Managed Care Value Program
(2/16, Mindy Yochelson, Bloomberg BNA) reports “...[HHS Secretary Tom Price] told the Senate Finance Committee prior to his confirmation that he wants Medicare Advantage plans to have more flexibility in how they may design their benefits. The program, known as Medicare Advantage Value-Based Insurance Design Model (VBID), ‘falls squarely under that umbrella,’ Mark Fendrick, who directs the Center for Value-Based Insurance Design at the University of Michigan, said. The expansion of VBID in Medicare Advantage to all 50 states is one of the few ideas with bipartisan support, he said. Price's comment ‘backs that up,’ he told Bloomberg BNA Feb. 13.” Full
Digital Strategies for Patient Engagement
(2/16, Chris Zant, STAT) comments “...So what does a great patient engagement program platform look like? It provides consistent high-touch interactions across channels (e.g., companion app, portal, phone, text, and chat). It enables the care network to collaborate with HCPs, families and other care team members. It provides a vehicle for internal and external data analysis to bring unique insights into patient treatment and interactions and demonstrate real-world evidence.” Full
DiabetesSisters Recruiting Voices to Help Improve Research
(2/17, Mike Hoskins, HealthLine.com) reports “...This is a much-needed effort, as the patient community has been pointing out for years that clinical trials aren't traditionally designed with us -- the people actually living with diabetes -- in mind...A few attempts to tackle this problem to date include some interesting university projects, the emerging crowdsourcing platform VitalCrowd, and of course work by PCORI. The latter is actually involved in helping DiabetesSisters, a community 13,000 strong, to build out their new DiabetesSistersVoices program... Full
Comparative Effectiveness of Adjuvant Chemoradiotherapy after Gastrectomy among Older Patients with Gastric Adenocarcinoma: A SEER-Medicare Study
Yeh JM, Tramontano AC, Hur C, Schrag D.
February 15, 2017, Gastric Cancer
Progress in Evidence-Based Medicine: A Quarter Century On
Prof Benjamin Djulbegovic, MD, Prof Gordon H Guyatt, MD
February 16, 2017, The Lancet
The Lancet Link
Value-Based Insurance Design
Sharan AD, Schroeder GD, West ME, Vaccaro AR.
March 2017, Clinical Spine Surgery
PCORnet Best Practice Sharing Session: The Brain Health Registry Caregiver and Study Partner Portal: An Alzheimer’s PPRN Tool to Facilitate Patient-centered Clinical Research
March 7, 2017
12:00 - 1:00PM EST